Interaction of the cannabinoid and opioid systems in the modulation of nociception

International Review of Psychiatry

Volumn 21, Issue 2 SPEC. ISS., 2009, Pages 143-151

  Welch, Sandra P ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ANANDAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABIS; CODEINE; DELTA8 TETRAHYDROCANNABINOL; DRONABINOL; DYNORPHIN ANTIBODY; ENDOCANNABINOID; MORPHINE; NABILONE; NORBINALTORPHIMINE; OPIATE; OPIATE RECEPTOR; RIMONABANT;

ANTINOCICEPTION; ARTHRITIS; CHRONIC PAIN; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; HUMAN; LOW DRUG DOSE; NAUSEA AND VOMITING; NOCICEPTION; NONHUMAN; PAIN; PAIN THRESHOLD; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

ANALGESIA; ANALGESICS; ANALGESICS, OPIOID; ANIMALS; CANNABINOIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; HUMANS; NOCICEPTORS; OPIOID-RELATED DISORDERS; PAIN;

EID: 67651028391     PISSN: 09540261     EISSN: 13691627     Source Type: Journal    
DOI: 10.1080/09540260902782794     Document Type: Review

References (92)

1. Ballantyne, J.C., & Shin, N.S. (2008). Efficacy of opioids for chronic pain: A review of the evidence. Clinical Journal of Pain, 24, 469-478.
2. Berman, Y., Devi, L., & Carr, K.D. (1995). Effects of streptozotocin-induced diabetes on prodynorphin-derived peptides in rat brain regions. Brain Research, 685, 129-134.
3. Bisogno, T., Cascio, M.G., Saha, B., Mahadevan, A., Urbani, P., Minassi, A. et al. (2006). Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. Biochim Biophys Acta, 1761, 205-212.
4. Bodnar, R.J. (2008). Endogenous opiates and behavior: 2007. Peptides, 29, 2292-2375.
5. Brown, A.J. (2007). Novel cannabinoid receptors. British Journal of Pharmacology, 152, 567-575.
6. Buckley, N.E. (2008). The peripheral cannabinoid receptor knockout mice: An update. British Journal of Pharmacology, 153, 309-318.
7. Calignano, A., La Rana, G., & Giuffrida, A. (1998). Control of pain initiation by endogenous cannabinoids. Nature, 394, 277-281. (Pubitemid 28335039)
8. Cherny, N., Ripamonti, C., Pereira, J., Davis, C., Fallon, M., McQuay, H. et al. (2001). Expert working group of the European association of palliative care network. Strategies to manage the adverse effects of oral morphine: An evidence-based report. Journal of Clinical Oncology, 19, 2542-2554.
9. Cheung, C.Y., & Tang, F. (1999). The effects of streptozotocin diabetes on ß-endorphin level and proopiomelanocortin gene expression in the rat pituitary. Neuroscience Letters, 261, 118-120.
10. Cichewicz, D.L., & McCarthy, E.A. (2003). Antinociceptive synergy between Δ9-tetrahydrocannabinol and opioids after oral administration. Journal of Pharmacology and Experimental Therapeutics, 304, 1010-1015.
11. Cichewicz, D.L., & Welch, S.P. (2003). Modulation of oral morphine antinociceptive tolerance and naloxone-precipitated withdrawal signs by oral Δ9-THC. Journal of Pharmacology and Experimental Therapeutics, 307, 812-817.
12. Civelli, O. (2008). The orphanin FQ/nociceptin (OFQ/N) system. Results in Problems of Cell Differentiation, 46, 1-25.
13. Cooper, Z.D., & Haney, M. (2008). Cannabis reinforcement and dependence: Role of the cannabinoid CB1 receptor. Addiction Biology, 13(2), 188-195.
14. Corchero, J., Avila, M.A., & Fuentes, J.A. (1997). Delta-9-tetrahydrocannabinol increases prodynorphin and proenkephalin gene expression in the spinal cord of the rat. Life Sciences, 61, PL39-43. (Pubitemid 27305585)
15. Cox, M.L, Haller, V.L., & Welch, S.P. (2007). The antinociceptive effect of delta 9-THC in the arthritic rat involves the CB2 cannabinoid receptor. European Journal of Pharmacology, 570, 50-56.
16. Cox, M.L., & Welch, S.P. (2004). The antinociceptive effect of Δ9-THC in the arthritic rat. European Journal of Pharmacology, 493, 65-74.
17. Cravatt, B.F., Demarest, K., Patricelli, M.P., Bracey, M.H., Giang, D.K., Martin, B.R. et al. (2001). Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proceedings of National Academy of Sciences, 98, 9371-9376. (Pubitemid 32743923)
18. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Nature. 1996 Nov 7;384(6604):83-87
19. Cravatt, B.F., & Lichtman, A.H. (2004). The endogenous cannabinoid system and its role in nociceptive behavior. Journal of Neurobiology, 61, 149-160.
20. Devane, W.A., Dysarz III, F.A., Johnson, M.R., Melvin, L.S., & Howlett, A.C. (1988). Determination and characterization of a cannabinoid receptor in rat brain. Molecular Pharmacology, 34, 605-613. (Pubitemid 19007296)
21. Devane, W.A., Hanus, L., Breuer, A., Pertwee, R.G., Stevenson, L.A., Griffin, G. et al. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258, 1946-1949. (Pubitemid 23026736)
22. Di Marzo, V., De Petrocellis, L., & Bisogno, T. (2005). The biosynthesis, fate and pharmacological properties of endocannabinoids. Handbook of Experimental Pharmacology, 168, 147-185.
23. Di Marzo, V., & De Petrocellis, L. (2006). Plant, synthetic, and endogenous cannabinoids in medicine. Annual Review of Medicine, 57, 553-574. (Pubitemid 43262007)
24. Di Marzo, V., & Petrosino, S. (2007). Endocannabinoids and the regulation of their levels in health and disease. Current Opinions in Lipidology, 18, 129-140. (Pubitemid 46412082)
25. Dinh, T.P., Freund, T.F., & Piomelli, D. (2002). A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chemistry and Physics of Lipids, 121, 149-158. (Pubitemid 36044549)
26. Fallucca, F., Tonnarini, G., Di Biase, N., D'Alessandro, M., & Negri, M. (1996). Plasma met-enkephalin levels in diabetic patients: Influence of autonomic neuropathy. Metabolism, 45, 1065-1068. (Pubitemid 26300304)
27. Fowler, C.J., Tiger, G., Ligresti, A., Lopez-Rodriguez, M.L., & Di Marzo, V. (2004). Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis - A difficult issue to handle. European Journal of Pharmacology, 492, 1-11. (Pubitemid 38624415)
28. Gardell, L.R., Ossipov, M.H., Vanderah, T.W., Lai, J., & Porreca, F. (2002). Dynorphin-independent spinal cannabinoid antinociception. Pain, 100, 243-248.
29. Ghosh, P., & Bhattacharya, S.K. (1979). Cannabis-induced potentiation of morphine analgesia in rat: Role of brain monoamines. Indian Journal of Medical Research, 70, 275-280. (Pubitemid 10216962)
30. Gidal, B. (2006). New and emerging treatment options for neuropathic pain. American Journal of Managed Care, 12, S269-278.
31. Gomes, I., Filipovska, J., & Jordan, B.A. (2002). Oligomerization of opioid receptors. Methods, 27, 358-365.
32. Gulyas, A.I., Cravatt, B.F., Braciey, M.H., Dinh, T.P., Piomelli, D., Boscia, F. et al. (2004). Segregation of two endocannabinoid-hydrolyzing enzymes into preand postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. European Journal of Neuroscience, 20, 441-458. (Pubitemid 38969629)
33. Haller, V.L., Cichewicz, D.L., & Welch, S.P. (2006). Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice. European Journal of Pharmacology, 546, 60-68.
34. Haller, V.L., Stevens, D.L., & Welch, S.P. (2008). Modulation of opioids via protection of anandamide degradation by fatty acid amide hydrolase. European Journal of Pharmacology, 600(1-3), 50-58.
35. Herzberg, U., Eliav, E., & Bennett, G.J. (1997). The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neuroscience Letters, 221, 157-160. (Pubitemid 27049222)
36. Hohmann, A.G., & Suplita, R.L. (2006). Endocannabinoid mechanisms of pain modulation. AAPS Journal, 8, E693-708.
37. Hosking, R.D., & Zajicek, J.P. (2008). Therapeutic potential of cannabis in pain medicine. British Journal of Anaesthesia, 101, 59-68.
38. Ibrahim, M.M., Deng, H., & Zvonok, A. (2003). Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: Pain inhibition by receptors not present in the CNS. PNAS, 100, 10529-10533. (Pubitemid 37071912)
39. Ibrahim, M.H., Porreca, F., Lai, J., Albrecht, P.J., Rice, F.L., Khodorova, A. et al. (2005). CB cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. PNAS, 102, 3093-3098. (Pubitemid 40299921)
40. Kawasaki, Y., Kohno, T., & Ji, R.R. (2006). Different effects of opioid and cannabinoid receptor agonists on C-fiber-induced extracellular signal-regulated kinase activation in dorsal horn neurons in normal and spinal nerve-ligated rats. Journal of Pharmacology and Experimental Therapeutics, 316, 601-607. (Pubitemid 43130986)
41. Ko, M.C., & Woods, J.H. (1999). Local administration of delta-9-tetrahydrocannabinol attenuates capsaicin-induced thermal nociception in rhesus monkeys: A peripheral cannabinoid action. Psychopharmacology, 143, 322-326.
42. Kogan, N.M., & Mechoulam, R. (2006). The chemistry of endocannabinoids. Journal of Endocrin Inv, 29, 3-14.
43. Ledent, C., Valverde, O., Cossu, G., Petitet, F., Aubert, J.F., Beslot, F. et al. (1999). Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science, 283, 401-404. (Pubitemid 129501104)
44. Li, J., Daughters, R.S., & Bullis, C. (1999). The cannabinoid receptor agonist WIN 55,212-2 mesylate blocks the development of hyperalgesia produced by capsaicin in rats. Pain, 81, 25-33. (Pubitemid 29199898)
45. Lichtman, A.H., & Martin, B.R. (1991). Spinal and supraspinal mechanisms of cannabinoid-induced antinociception. Journal of Pharmacol Exp Ther, 258, 517-523.
46. Lichtman, A.H., Sheikh, S.M., Loh, H.H., & Martin, B.R. (2001). Opioid and cannabinoid modulation of precipitated withdrawal in delta (9)-tetrahydrocannabinol and morphine-dependent mice. Journal of Pharmacol Exp Ther, 298, 1007-1014.
47. Lim, G., Sung, B., & Ji, R.R. (2003). Upregulation of spinal cannabinoid-1 receptors following nerve injury enhances the effects of win 55,212-2 on neuropathic pain behaviors in rats. Pain, 105, 275-283. (Pubitemid 37162497)
48. Mailleux, P., & Vanderhaeghen, J.J. (1992). Localization of cannabinoid receptor in the human developing and adult basal ganglia. Higher levels in the striatonigral neurons. Neurosci Letts, 148, 173-176.
49. Manzanares, J., Corchero, J., & Romero, J (1999). Pharmacological and biochemical interactions between opioids and cannabinoids. Trends in Pharmacological Sciences, 20, 287-294. (Pubitemid 29301682)
50. Mao, J., Price, D.D., & Lu, J. (2000). Two distinctive antinociceptive systems in rats with pathological pain. Neurosci Letts, 280(1), 13-16. (Pubitemid 30069562)
51. Martin, B.R., Sim-Selley, L.J., & Selley, D.E. (2004). Signaling pathways involved in the development of cannabinoid tolerance. Trends in Pharmacol Science, 25, 325-330. (Pubitemid 38692425)
52. Martin, M., Ledent, C., Parmentier, M., Maldonado, R., & Valverde, O. (2000). Cocaine, but not morphine, induces conditioned place preference and sensitization to locomotor responses in CB1 knockout mice. European Journal of Neuroscience, 12, 4038-4046. (Pubitemid 30836291)
53. Martin, W.J., Loo, C.M., & Basbaum, A.I. (1999). Spinal cannabinoids are antiallodynic in rats with persistent inflammation. Pain, 82, 199-205.
54. Mason, D.L., & Welch, S.P. (1999a). A diminution of 9-tetrahydrocannabinol modulation of dynorphin A-(1-17) in conjunction with tolerance development. European Journal of Pharmacology, 381, 105-111.
55. Mason, D.J., & Welch, S.P. (1999b). Cannabinoid modulation of dynorphin A: Correlation to cannabinoid-induced antinociception. European Journal of Pharmacology, 378, 237-248.
56. Matsuda, L.A., Lolait, S.J., Brownstein, M.J., Young, A.C., & Bonner, T.I. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346, 561-564. (Pubitemid 20238806)
57. Mechoulam, R., Lander, N., Srebnik, M., Zamir, I., Breuer, A., Shalita, B. et al. (1984). Recent advances in the use of cannabinoids as therapeutic agents. In S. Agurell, W. Dewey & R. Willette (Eds.), The cannabinoids: Chemical, pharmacological and therapeutic aspects (pp. 777-793). New York: Academic Press.
58. Moss, D.E., & Johnson, R.L. (1980). Tonic analgesic effects of delta 9 tetrahydrocannabinol as measured with the formalin test. European Journal of Pharmacology, 61, 313-315.
59. Munro, S., Thomas, K.L., & Abu-Shaar, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature, 365, 61-65. (Pubitemid 23305569)
60. 9-THC), morphine, and a Δ9-THC-morphine combination in healthy subjects under experimental pain conditions. Pain, 105, 79-88.
61. Noyes Jr, R., Brunk, S.F., Avery, D.A., & Canter, A.C. (1975). The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clinical Pharmacology Therapy, 18, 84-89.
62. Price, D.D., Von der Gruen, A., Miller, J., Rafii, A., & Price, C. (1985). A psychophysical analysis of morphine analgesia. Pain, 22, 261-269.
63. Pugh, G.J., Smith, P.B, & Dombrowski, D.S. (1996). The role of endogenous opioids in enhancing the antinociception produced by the combination of delta-9-THC and morphine in the spinal cord. Journal of Pharmacology and Experimental Therapeutics, 279, 608-616.
64. Richardson, J., Aanonsen, L., & Hargreaves, K.M. (1997). SR141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. European Journal of Pharmacology, 319, 3R-5R. (Pubitemid 27056064)
65. Rinaldi-Carmona, M., Barth, F., Millan, J., Deroq, J.M., Casellas, P., Congy, C. et al. (1998). SR144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. Journal of Pharmacology and Experimental Therapeutics, 284, 644-650. (Pubitemid 28086654)
66. Rinaldi-Carmona, M., Barth, F., Heaulme, M., Shire, D., Calandra, B., Congy, C. et al. (1994). SR141716A, a potent and selective antagonist of the cannbinoid receptor. FEBS Lett, 350, 240-244. (Pubitemid 24268029)
67. Rios, C., Gomes, I., & Devi, L.A. (2006). Opioid and CB1 cannabinoid receptor interactions: Reciprocal inhibition of receptor signaling and neuritogenesis. British Journal of Pharmacology, 148, 387-395. (Pubitemid 43882074)
68. Roberts, J.D., Gennings, C., & Shih, M. (2006). Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. European Journal of Pharmacology, 13, 530(1-2), 54-58. (Pubitemid 43037124)
69. Rowen, D.W., Embrey, J.P., & Moore, C.H. (1998). Antisense oligodeoxynucleotides to the kappa1 receptor enhance delta9-THC-induced antinociceptive tolerance. Pharmacology, Biochemistry and Behavior, 59, 399-404.
70. Siegling, A., Hofmann, H.A., & Denzer, D. (2001). Cannabinoid CB(1) receptor upregulation in a rat model of chronic neuropathic pain. European Journal of Pharmacology, 415, R5-7. (Pubitemid 32197627)
71. Salio, C., Fischer, J., & Franzoni, M.F. (2001). CB1-cannabinoid and mu-opioid receptor co-localization on postsynaptic target in the rat dorsal horn. Neuroreport, 12, 3689-3692. (Pubitemid 33105152)
72. Sañudo-Peña, M.C., Tsou, K., & Walker, J.M. (1999). Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sciences, 65, 703-713. (Pubitemid 29362776)
73. Sim, L.J., Selley, D.E., Dworkin, S.I., & Childers, S.R. (1996). Effects of chronic GTPγS morphine administration on mu opioid receptor-stimulated [35S]autoradiography in rat brain. Journal of Neuroscience, 16, 2684-2692. (Pubitemid 26122684)
74. Sim-Selley, L.J., & Martin, B.R. (2002). Effect or chronic administration of R-(+)-[2,3-Dihydro-5-mthyl-3-[(morpholinyl)methyl] pyrrolo[1,2,3,-dej-1,4-benzoxazinyl]-(1naphthalenyl)methanonemesylate(WIN55. 212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice. Journal of Pharmacology and Experimental Therapeutics, 303, 36-44.
75. Smith, F.L., Fujimori, K., Lowe, J., & Welch, S.P. (1998). Characterization of delta 9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats. Pharmacology, Biochemistry and Behavior, 60, 183-191.
76. Smith, P.A., Sim-Selley, L.J., Selley, D.E., & Welch, S.P. (2007). Low dose combination of morphine and Δ9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors. European Journal of Pharmacology, 571, 129-137.
77. Smith, P.B., Welch, S.P., & Martin, B.R. (1994). Interactions between delta 9-tetrahydrocannabinol and kappa opioids in mice. Journal of Pharmacology and Experimental Therapeutics, 268, 1382-1387.
78. Sofia, R.D., Nalepa, S.D., & Harakal, J.J. (1973). Anti-edema and analgesic properties of delta-9-tetrahydrocannabinol (THC). Journal of Pharmacology and Experimental Therapeutics, 186, 646-655.
79. Strangman, N.M., Patrick, S.L., & Hohmann, A.G. (1998). Evidence for a role of endogenous cannabinoids in the modulation of acute and tonic pain sensitivity. Brain Research, 813, 323-328.
80. Tanda, G., & Goldberg, S.R. (2003). Cannabinoids: Reward, dependence, and underlying neurochemical mechanisms - A review of recent preclinical data. Psychopharmacology, 169, 115-134. (Pubitemid 37129963)
81. Trescott, A.M., Datta, S., Lee, M., & Hansen, H. (2008). Opioid pharmacology. Pain Physician, 11, S133-153.
82. Tseng, L. (2001). Evidence for e-opioid receptor-mediated b-endorphin-induced analgesia. Trends in Pharmacological Sciences, 22, 623-630.
83. Valenzano, K.J., Tafesse, L., & Lee, G. (2005). Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, gw405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology, 48, 658-672. (Pubitemid 40462406)
84. Vigano, D., Rubino, T., & Parolaro, D. (2005). Molecular and cellular basis of cannabinoid and opioid interactions. Pharmacology, Biochemistry and Behavior, 81, 360-368.
85. Vigano, D., Cascio, M.G., Rubino, T., Fezza, F., Vaccani, A., Di Marzo, V. et al. (2003). Chronic morphine modulates the contents of the endocannabinoid, 2-arachidonoyl glycerol, in rat brain. Neuropsychopharmacology, 28, 1160-1167.
86. Vigano, D., Valenti, M., Cascio, M.G., Di Marzo, V., & Parolaro, D. (2004). Changes in endocannabinoid levels in a rat model of behavioral sensitization to morphine. European Journal of Neuroscience, 20, 1849-1857. (Pubitemid 39471578)
87. Walker, J.M., Hohmann, A.G., & Martin, W.J. (1999). The neurobiology of cannabinoid analgesia. Life Sciences, 65, 665-673.
88. Walker, J.M., & Huang, S.M. (2002). Endocannabinoids in pain modulation. Prostaglandins, Leukotrienes and Essentential Fatty Acids, 66, 235-242.
89. Williams, I.J., Stevens, D.L., Haller, V.L., & Welch, S.P. (2008). Decreased basal endogenous opioid levels in diabetic rodents: Effects on morphine and delta-9-tetrahydrocannabinoidinduced antinociception. European Journal of Pharmacology, 584, 78-86.
90. Wotherspoon, G., Fox, A., & McIntyre, P. (2005). Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience, 135, 235-245. (Pubitemid 41219752)
91. Zimmer, A., Zimmer, A.M., & Hohmann, A.G. (1999). Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proceedings of the National Academy of Science, 96, 5780-5785. (Pubitemid 29234695)
92. Zimmer, A., Valjent, E., & Konig, M. (2001). Absence of delta-9-tetrahydrocannabinol dysphoric effects in dynorphindeficient mice. Journal of Neuroscience, 21, 9499-9505. (Pubitemid 33096894)